An International Inter-Laboratory Digital PCR Study Demonstrates High Reproducibility for the Measurement of a Rare Sequence Variant

Abstract

This study tested the claim that digital PCR (dPCR) can offer highly reproducible quantitative measurements in disparate labs. Twenty-one laboratories measured four blinded samples containing different quantities of a KRAS fragment encoding G12D, an important genetic marker for guiding therapy of certain cancers. This marker is challenging to quantify reproducibly using qPCR or NGS due to the presence of competing wild type sequences and the need for calibration. Using dPCR, eighteen laboratories were able to quantify the G12D marker within 12% of each other in all samples. Three laboratories appeared to measure consistently outlying results; however, proper application of a follow-up analysis recommendation rectified their data. Our findings show that dPCR has demonstrable reproducibility across a large number of laboratories without calibration and could enable the reproducible application of molecular stratification to guide therapy, and potentially for molecular diagnostics.SIGNIFICANCE STATEMENTThe poor reproducibility of molecular diagnostic methods limits their application in part due to the challenges associated with calibration of what are relative measurement approaches. In this study we investigate the performance of one of the only absolute measurement methods available today, digital PCR (dPCR), and demonstrated that when compared across twenty-one laboratories, dPCR has unprecedented reproducibility. These results were achieved when measuring a challenging single nucleotide variant and without calibration to any reference samples. This opens the possibility for dPCR to offer a method to transform reproducibility in the molecular diagnostic field, both by direct use as well as in support of other currently used clinical methods.

Using Digital Droplet Polymerase Chain Reaction to Detect the Mosaic GNAS Mutations in Whole Blood DNA or Circulating Cell-Free DNA in Fibrous Dysplasia and McCune-Albright Syndrome

“…Consequently, the development of a sensitive and non-invasive test is crucial for an early molecular diagnosis. Digital droplet polymerase chain reaction™ (ddPCR™) is a breakthrough technology of quantitative PCR useful for a targeted detection and quantification of rare events (12,13). Moreover, the emergence of the new non-invasive strategy to detect and monitor mutations in the circulating cell-free DNA (ccfDNA) from patients presented with a cancer, (named "liquid biopsies"), offers new prospects for the molecular diagnosis of FD/MAS (14,15).…”

“…ccfDNA Nested-PCR [13,20] MEMO-PCR [10] PNA clamping [20] PNA-NGS [22] Overall detection rate (all patients) 80% (4/5) * 58.3% (…”

Evaluation of epigenetic methylation biomarkers for the detection of colorectal cancer using droplet digital PCR

“…ML-ddPCR offers the potential to overcome some of the limitations of previous tests. The system is automated and can provide a high-throughput methodology that is highly reliable and reproducible without the need for serial dilution calibration [11]. Furthermore, ML-ddPCR is 25-fold more sensitive when compared to conventional ML-PCR which is critically important in assessing the inherently small amounts of circulating tumour DNA (ctDNA) obtained from blood samples [12].…”